Last reviewed · How we verify
NCT04873050: SWEET
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
Phase 4 trial testing Semaglutide Pen Injector [Ozempic] in Pre Diabetes in 102 participants. Currently enrolling.
1 January 2026
Quick facts
| Lead sponsor | Woman's |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 102 |
| Start date | 13 January 2022 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 March 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Semaglutide Pen Injector [Ozempic] — full drug profile →
- Placebo semaglutide pen injector
Conditions studied
- Pre Diabetes — all drugs for Pre Diabetes →
- Postpartum Disorder — all drugs for Postpartum Disorder →
Sponsor
Woman's — full company profile →
Who can join
Adults 18 to 45, female only, with Pre Diabetes or Postpartum Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabetes recovery and reduce future risk of T2DM in young women.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04873050
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Semaglutide Pen Injector [Ozempic]
Trials testing the same drug.
- NCT06449625 — Semaglutide in Auto-HSCT · Phase 2 · not yet recruiting
- NCT05950516 — Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes · Phase 3 · unknown
- NCT05071898 — Pharmacogenetics of Response to GLP1R Agonists · Phase 1 · recruiting
- NCT05857085 — Novel Therapeutics and Endothelial Dysfunction in T1DM Patients · Phase 4 · completed
- NCT05606471 — Glucagon-like Peptide-1 Agonism With Very Low Calorie Diets · Phase 4 · unknown
Other recruiting trials for Pre Diabetes
Currently open trials in the same condition.
- NCT07252700 — Preventing Diabetes: Impact of an EMR-Based Intervention for Enhanced Pre-Diabetes Management in Primary Care · NA · recruiting
- NCT06986161 — Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals · NA · recruiting
- NCT06426277 — Effectiveness of the Brazilian Diabetes Prevention Program · NA · recruiting
- NCT06387797 — Primary and Secondary Prevention of Type 2 Diabetes Mellitus in Clark County · NA · recruiting
- NCT06555952 — MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors · NA · recruiting
Other Woman's trials
Trials by the same sponsor.
- NCT06057805 — The PPCGMS Intervention After GDM Trial · NA · terminated
- NCT05067075 — The CGMS in GDM Labor and Delivery Study · NA · completed
- NCT04948112 — Effectiveness of CGMS Vs. Self-monitoring Blood Glucose (SMBG) in Woman with Gestational Diabetes · NA · completed
- NCT04726085 — Ibuprofen Versus Indomethacin Following Emergent Cerclage Placement · NA · terminated
- NCT04256889 — Use Of Nfant(R) Technology Feeding System For Infants Less Than 30 Weeks GA · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04873050 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Woman's
- Last refreshed: 13 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04873050.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing